Scarica l'app Stockscreener
3.44
5.52%
0.18
Dopo l'orario di chiusura:
3.49
0.05
+1.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.26
Aprire:
$3.22
Volume 24 ore:
341.89K
Relative Volume:
0.26
Capitalizzazione di mercato:
$19.68M
Reddito:
-
Utile/perdita netta:
$-16.60M
Rapporto P/E:
-3.8652
EPS:
-0.89
Flusso di cassa netto:
$-23.48M
1 W Prestazione:
+12.05%
1M Prestazione:
-25.05%
6M Prestazione:
-76.66%
1 anno Prestazione:
-85.58%
Intervallo 1D:
$3.17
$3.46
Intervallo di 1 settimana:
$3.00
$3.46
Portata 52W:
$2.814
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Nome
Briacell Therapeutics Corp
Settore
Industria
Telefono
(604) 921-1810
Indirizzo
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Confronta BCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.44 | 20.80M | 0 | -16.60M | -23.48M | -0.89 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-14 | Iniziato | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Borsa (BCTX) Ultime notizie
(BCT) Market Dynamics and Trading Signals (BCT:CA) - news.stocktradersdaily.com
When (BCT) Moves Investors should Listen (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Corp - Baystreet.ca
Cardiol Therapeutics Inc. - Baystreet.ca
BriaCell advances cancer treatment with Bria-OTS in clinical study By Investing.com - Investing.com South Africa
BriaCell Bria-OTS? Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor - marketscreener.com
BriaCell advances cancer treatment with Bria-OTS in clinical study - Investing.com
BriaCell Advances Bria-OTS in Cancer Immunotherapy with New Study Phase - TipRanks
BriaCell (BCTX): Advances in Cancer Treatment with Bria-OTS | BC - GuruFocus
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Dos - GuruFocus
BriaCell (BCTX): Advances in Cancer Treatment with Bria-OTS | BCTX Stock News - GuruFocus
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety - GlobeNewswire
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor - Yahoo Finance
(BCT) Advanced Equity Analysis (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell (BCTX) Showcases Promising Data at ASCO 2025 | BCTX Sto - GuruFocus
BriaCell Therapeutics Reports Promising Phase 2 Results for Metastatic Breast Cancer Treatment - TipRanks
BriaCell to Showcase Survival and Clinical Benefit Data at ASCO Meeting Next Week - marketscreener.com
BriaCell (BCTX) Showcases Promising Data at ASCO 2025 | BCTX Stock News - GuruFocus
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 - The Manila Times
‘Don’t Doubt UNH Yet,’ Top JPMorgan Analyst Defends UnitedHealth Stock amid Recent Volatility - The Globe and Mail
Breakthrough: BriaCell's New Breast Cancer Drug Shows 13.4-Month Survival Rate, Beating Standard Therapies - Stock Titan
OpenAI CEO Sam Altman Admits Even They Are ‘a Little Bit Scared’ of What They’re Building—But That’s a Good Thing - The Globe and Mail
Stock Market News Today, 5/22/25 – Futures Flat, Post Deficit-Fear-Driven Sell-Off - The Globe and Mail
Moderna Stock Looks Ripe for a Short Squeeze - The Globe and Mail
(BCT) Trading Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell CEO Letter to Shareholders | BCTX Stock News - GuruFocus
BriaCell (BCTX) Reports Promising Advances in Cancer Treatment Studies | BCTX Stock News - GuruFocus
BriaCell Therapeutics Advances in Cancer Immunotherapy with Promising Clinical Results - TipRanks
Briacell Therapeutics CorpBria-Imt Receives FDA Fast Track Designation For Phase 3 Study - marketscreener.com
BriaCell CEO Letter to Shareholders - GlobeNewswire
Clinical Trial Breakthrough: BriaCell's Breast Cancer Therapy Shows 83% Success Rate, Surpassing Current Standard - Stock Titan
Public market insider buying at CGI (GIB) - The Globe and Mail
BriaCell Therapeutics (OTCMKTS:BCTXF) Stock Price Up 0.7% – Here’s Why - Defense World
Cisco Systems: A Safe Investment or a Stagnant Giant? - The Globe and Mail
(BCT) On The My Stocks Page (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics (CVE:BCT) Shares Down 3.8% – Here’s Why - Defense World
(BCT) Comprehensive Trading Strategy Report (BCT:CA) - news.stocktradersdaily.com
WonderFi Jumps Over 35% on Robinhood Acquisition News - The Globe and Mail
HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Operating Results - The Globe and Mail
(BCT) Risk-Controlled Trading Report (BCT:CA) - news.stocktradersdaily.com
Why Are Investors Talking About Roblox Stock? - The Globe and Mail
(BCT) Trading Advice (BCT:CA) - news.stocktradersdaily.com
2 Cash-Producing Stocks to Keep an Eye On and 1 to Avoid - The Globe and Mail
(BCT) Investment Performance Report (BCT:CA) - news.stocktradersdaily.com
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - PR Newswire
BriaCell (BCTX) Highlights Promising Biomarkers in Metastatic Br - GuruFocus
BriaCell Therapeutics Corp. - Baystreet.ca
Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com
How To Trade (BCT) (BCT:CA) - news.stocktradersdaily.com
BriaCell’s Phase 3 Data Shows Promise for Metastatic Breast Cancer Treatment - TipRanks
Briacell Therapeutics Corp Azioni (BCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):